Literature DB >> 3069479

Inter- and intraindividual differences in oral chlorambucil pharmacokinetics.

P Hartvig1, B Simonsson, G Oberg, I Wallin, H Ehrsson.   

Abstract

Inter- and intraindividual variation in the pharmacokinetics of oral chlorambucil was investigated in patients with chronic lymphocytic leukaemia. Five patients were given in randomized order 15, 40, 60 and 70 mg chlorambucil p.o. and plasma was analyzed for chlorambucil and its cytotoxic metabolite phenyl acetic acid mustard. The area under the plasma concentration-time curve of chlorambucil varied two- to fourfold between patients at each dose level. The AUC of the metabolite was higher and showed twofold interindividual variation. The intraindividual dose-corrected AUCcs also varied twofold. No dose dependency of the dose corrected AUC was seen either for chlorambucil or the metabolite. Elimination of both compounds form plasma was rapid, with half-lives of 1.01 and 1.94, respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069479     DOI: 10.1007/bf00558252

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia.

Authors:  W H Knospe; V Loeb; C M Huguley
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

2.  Comparative physico-chemical properties, biological effects, and disposition in mice of four nitrogen mustards.

Authors:  D Godenèche; J C Madelmont; M F Moreau; R Plagne; G Meyniel
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

Authors:  H Ehrsson; I Wallin; S O Nilsson; B Johansson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Effect of food on pharmacokinetics of chlorambucil and its main metabolite, phenylacetic acid mustard.

Authors:  H Ehrsson; I Wallin; B Simonsson; P Hartvig; G Oberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  The metabolism of chlorambucil.

Authors:  A McLean; D Newell; G Baker; T Connors
Journal:  Biochem Pharmacol       Date:  1980-07-15       Impact factor: 5.858

6.  Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease.

Authors:  A McLean; R L Woods; D Catovsky; P Farmer
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

7.  Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report.

Authors:  D S Alberts; S Y Chang; H S Chen; B J Larcom; S E Jones
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

8.  Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

Authors:  D R Newell; A H Calvert; K R Harrap; T J McElwain
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

9.  Determination of chlorambucil in plasma by GLC with selected-ion monitoring.

Authors:  H Ehrsson; S Eksborg; I Wallin; Y Mårde; B Joansson
Journal:  J Pharm Sci       Date:  1980-06       Impact factor: 3.534

10.  Inhibition of human tumour clonogenicity by chlorambucil and its metabolites.

Authors:  G E Goodman; A McLean; D S Alberts; S Y Chang
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

  10 in total
  2 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.

Authors:  L Bastholt; C J Johansson; P Pfeiffer; L Svensson; S A Johansson; P O Gunnarsson; H Mouridsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.